about
Association of gastric disease with polymorphisms in the inflammatory-related genes IL-1B, IL-1RN, IL-10, TNF and TLR4Midgut pain due to an intussuscepting terminal ileal lipoma: a case reportRefractory celiac disease.Relevance of folate metabolism in the pathogenesis of colorectal cancer.A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up.Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study.Post-ERCP Emphysematous Cholecystitis in a Young Woman: A Rare and Potentially Fatal Complication.Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.Clinical Outcome of Patients with Raised Intraepithelial Lymphocytes with Normal Villous Architecture on Duodenal Biopsy.Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease.Changes in Presentation of Celiac Disease in Ireland From the 1960s to 2015.Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland.Acute granulomatous hepatitis in an immunosuppressed patient secondary to Q fever.The role of endoscopic intervention in the management of inflammatory pancreatic fluid collections.CMV pneumonitis in an immunosuppressed Crohn's disease patient.The clinical significance of antimicrobial serologic responses within an Irish Crohn's disease population.Adherence to colorectal polyp surveillance guidelines: is there a 'scope' to increase the opportunities for screening?A Case of Metastatic Renal Cell Cancer Presenting as Jaundice.Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis.A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up.One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.The potential role of gut microbiota in pancreatic disease: A systematic review.A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy.Isolated active ileitis: is it a mild subtype of Crohn's disease?Inappropriate colonoscopic surveillance of hyperplastic polyps.The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI).Eosinophilic oesophagitis: an Irish experience.A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.Delayed massive hemobilia after biliary stenting.Multicenter experience from the UK and Ireland of use of lumen-apposing metal stent for transluminal drainage of pancreatic fluid collections.Safety of lumen-apposing metal stents (LAMS) for pancreatic fluid collection drainage.A coincidence or a rare occurrence? A case of plasmablastic lymphoma of the small intestines following infliximab treatment for Crohn's disease.Transvenous Liver Biopsy via the Femoral VeinEffect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective studySerum mutant K-ras in the colorectal adenoma-to-carcinoma sequence. Implications for diagnosis, postoperative follow-up, and early detection of recurrent diseaseHost cytokine responses to Helicobacter pylori: an important determinant of clinical outcomeThe development of hepatic granulomas following interferon-alpha2b therapy for chronic hepatitis C infectionExtensive forearm deep venous thrombosis following a severe infliximab infusion reactionColonoscopy completion rates--are we prepared for a national screening programme?
P50
Q33576143-DEF7F606-7324-4C91-901D-9B6122947145Q33698469-1DF2EC3F-B2C4-47C4-AD01-0AEA8CC2C210Q33964140-0C7F4C29-7632-41ED-8FBE-5B4AF58F3DC5Q34350336-71A7C2AE-2769-408A-935A-AD445A0BA51EQ35595377-B99618C9-7803-4C85-A928-86476A70BD5BQ35595450-AA7D206E-392F-4BA8-A059-4DDBFE6C0A76Q37736392-7D1C3B9A-6CA4-4133-B2D0-A1997467B430Q37869193-12C5F3A5-FDB1-421A-842C-B0489B0AEBC8Q38640045-A9592368-D8E8-4C4E-A3BB-5CE1EE2A3BFDQ38782449-C32BD668-860D-4C22-8596-5680F78F3CA6Q38904535-B601DE89-050B-43FF-A43C-A115ED300CC9Q39043841-DFCE7033-E832-4F82-922A-E47767345B2EQ39887184-CE0C06F8-514F-46D0-91CE-4955495EB4B9Q40055286-E583B875-1906-46B4-87A6-478C1AFF585EQ40397670-FB98EF7E-2522-4C23-8291-CE2860D135E7Q41759232-DAEB36CA-1F77-498D-ABFF-AF632761670CQ45417563-2958DD3C-AC13-4E3B-9E21-490F0B6A389CQ45899461-6F753121-0F1E-4FE7-92C9-F762411D9362Q46216809-8169D540-42CB-406C-8291-E9685ED8C135Q46604015-A3536DE3-2BAF-41EE-BE43-72006082299AQ46968191-E5A59009-19C2-4B82-AD19-1036C707D6FEQ47769457-1558F176-B3A5-494C-85A5-B5D1EE2D08BDQ47946363-6C444AA3-B290-4C73-BF47-41C382D688A1Q48064545-889BF356-B66D-423C-B173-839F32277AF7Q50921326-3A297C58-E3D2-466D-BAD2-16EB5829EA02Q51004509-5BF00E6A-47A9-4F3C-80E9-0DA4E9A6337BQ51246038-0320C287-65DE-46F7-B3D2-9B4E5D141D1AQ51409727-0349C4A1-6920-47CC-A446-E94A8A80B05EQ51580727-6C3604CF-1152-43A1-9513-35E49C881D2CQ51800707-7143E3A7-289B-4559-8906-DAABB212F995Q52677945-B92D3CB0-F69A-4F26-8E46-9EFAE679E787Q52812383-E77DB3CC-1E55-4CA6-A083-87EA6078F159Q53348310-6EA9C890-BD3F-4669-8430-BE1825B93C53Q57910814-187E10B5-C03B-483E-835F-9120520F1999Q60644114-526D75C2-EC3D-414F-90D7-5C162AA3E5DEQ73808616-96FDA21C-3187-4626-9ADC-8B0ED8006BA3Q74325653-0F73B41D-0E5C-40BA-8474-A856CCB274A2Q77688973-140E00FE-2FC7-4AB4-883D-2EF24C7F84A1Q80465143-EE058F9E-1FEE-44C1-A7BB-04EEA37D3B34Q80496635-45C20E77-A788-473C-938B-69B8E144BB7E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Barbara M Ryan
@ast
Barbara M Ryan
@en
Barbara M Ryan
@es
Barbara M Ryan
@nl
type
label
Barbara M Ryan
@ast
Barbara M Ryan
@en
Barbara M Ryan
@es
Barbara M Ryan
@nl
altLabel
Barbara Ryan
@en
prefLabel
Barbara M Ryan
@ast
Barbara M Ryan
@en
Barbara M Ryan
@es
Barbara M Ryan
@nl
P106
P1153
23670504000
P21
P31
P496
0000-0001-8400-9202